Fresenius Medical Care (FME.DE) Aktsia Kursus

Fresenius Medical Care Kursus

XETRA·SULETUD
36,72
​
Turg suletud

Käive kasvas 6,0 % aastas viimase 19 aasta jooksul 19,63 B EUR-ni. Kasum aktsia kohta kasvas 4,9 % aastas viimase 19 aasta jooksul. Fresenius Medical Care netomarginaal on nüüd 5,0 %, valdavalt stabiilne 5,5 %-lt mõni aasta tagasi. Fresenius Medical Care pakub praegu umbes 3,92 % dividenditootlust. Väljamaksesuhe on umbes 42 % kasumist. Dividend kasvas 6,8 % aastas viimase 19 aasta jooksul. Analüütikute hinnasihi mediaan on 46,92 EUR, st üle praegust hinda 27,8 %. 27 analüütikust 11 soovitab osta — üldine konsensus on Hoia.

Fresenius Medical Care aktsiahinnad

Hangi need andmed Eulerpool API kaudu

100 000 päringut/kuus tasuta · krediitkaarti pole

Fresenius Medical Care ärimudel ja aktsia analüüs

Fresenius Medical Care AG on globaalselt juhtiv ettevõte dialüüsi ja neeruravi valdkonnas. Ettevõte asutati 1996. aastal, kui Fresenius AG ühendas oma dialüüsiettevõtte USA ettevõttega National Medical Care (NMC). Täna opereerib Fresenius Medical Care üle 120 riigi ja töötab seal umbes 120 000 inimest. Ettevõtte käitab üle 3 900 dialüüsi keskuse üle maailma ning teenindab ligikaudu 345 000 dialüüsi patsienti. Fresenius Medical Care ärimudel on suunatud kroonilise neeruhaigusega patsientide elukvaliteedi parandamisele, pakkudes kvaliteetseid dialüüsiravi, neeruravivalmistisi ja ravitehnoloogiaid. Fresenius Medical Care pakub oma patsientidele terviklikku toote- ja teenusvalikut, mis ulatub diagnoosimisest ravini ning võimaldab individuaalset patsienditöötlust. Fresenius Medical Care põhikompetentsiks on dialüüsi toodete ja tehnoloogiate arendamine ning tootmine. Ettevõte pakub laia valikut dialüüsimasinaid ja tarvikuid, mida saab kasutada haiglates, kliinikutes ja dialüüsi keskustes toimuva dialüüsiravi toetamiseks. Lisaks pakub ettevõte dialüüsi patsientide vajadustele kohandatud meditsiinilisi lahendusi, sealhulgas tehisneerusid, dialüüsifiltreid ja muid meditsiiniseadmeid. Fresenius Medical Care viib ka läbi ulatuslikke uurimis- ja arendustegevusi, et luua innovaatilisi tehnoloogiaid ning tooteid ja teenuseid, mis saavad parandada dialüüsi patsientide elu. Diagnostikatoodete osas pakub Fresenius Medical Care erinevaid labori- ja testilahendusi, mida kasutatakse dialüüsi patsientide jälgimiseks ning tüsistuste ja infektsioonide õigeaegseks diagnoosimiseks. Ettevõte pakub ka terviklikku meditsiiniseadmete ja tarvikute valikut, mida saab kasutada koduses dialüüsis olevate patsientide toetamiseks. Fresenius Medical Care opereerib kolmes ärisegmentis: dialüüsi tooted, dialüüsi teenused ja haiglate tooted. Dialüüsi toodete segmendis tegeleb ettevõte dialüüsimasinade ja tarvikute arendamise, tootmise ja turustamisega. Dialüüsi teenuste segmendis opereerib ettevõte mitmesuguseid dialüüsi kesku ning osutab dialüüsiravi, mida teostab mitmevaluline spetsialistide meeskond. Ettevõte opereerib ka laborivõrgustikku, mis pakub diagnostikalahendusi dialüüsi patsientidele. Haiglate toodete segmendis pakub Fresenius Medical Care erinevaid meditsiiniseadmeid ja lahendusi, mis aitavad parandada patsientide kliinilist ravi, sealhulgas afereesisüsteeme, infusioonisüsteeme ja patsientide monitoorimisseadmeid. Kogu oma ajaloo vältel on Fresenius Medical Care saanud arvukalt auhindu ja tunnustusi, sealhulgas Baden-Württembergi riigi innovaatilise auhinna automatiseeritud dialüüsimasina arendamise eest, mis võimaldab paremat dialüüsi patsientide ravi tänu online-monitoorimissüsteemide ja intelligentsete algoritmide kombineerimisele. Üldiselt pakub Fresenius Medical Care AG terviklikku toote- ja teenusvalikut dialüüsi patsientidele ning on oluline mängija neeruravi valdkonnas. Ettevõte on pühendunud kroonilise neeruhaigusega patsientide elukvaliteedi parandamisele ning innovaatiliste tehnoloogiate ja meetodite arendamisele selle haiguse ravimiseks.

Korduma kippuvad küsimused Fresenius Medical Care aktsia kohta

Fresenius Medical Care AG is a leading global provider of dialysis products, services, and solutions for patients with chronic kidney failure. The company's business model revolves around providing high-quality dialysis care to patients in over 120 countries. Fresenius Medical Care AG offers a comprehensive range of dialysis machines, dialyzers, and other related products to ensure efficient and effective treatment. Furthermore, the company operates a network of dialysis clinics, providing personalized care for patients worldwide. With a focus on innovation, research, and development, Fresenius Medical Care AG continuously strives to enhance patient outcomes and improve the overall quality of life for individuals with kidney disease.

Fresenius Medical Care AG is primarily active in the healthcare industry.

The main competitors of Fresenius Medical Care AG in the market are DaVita Inc., Baxter International Inc., and B. Braun Melsungen AG.

Fresenius Medical Care AG is a leading global healthcare company specializing in dialysis products and services. Established in 1996, it stemmed from the merger of Fresenius AG and National Medical Care. With its headquarters in Germany, the company has expanded its reach worldwide, operating in nearly 150 countries. Fresenius Medical Care AG is renowned for its expertise in renal therapy, offering innovative dialysis machines, dialyzers, and related medical supplies. As a market leader, it provides life-saving treatments to millions of people suffering from chronic kidney disease. The company's commitment to delivering high-quality care and advancing renal healthcare has made Fresenius Medical Care AG a trusted name in the medical industry.

Fresenius Medical Care AG, a leading healthcare company, has achieved significant milestones throughout its history. It pioneered the development of advanced dialysis products and services, revolutionizing the treatment of end-stage renal disease. The company has established a global presence, operating in over 120 countries and serving millions of patients worldwide. Additionally, Fresenius Medical Care AG has continuously expanded its business through strategic acquisitions and collaborations, strengthening its position as a market leader in dialysis care. With a commitment to research and development, the company has achieved breakthrough innovations in dialysis technology, enhancing patient outcomes and quality of life. Overall, Fresenius Medical Care AG’s impressive achievements have solidified its reputation as a trusted provider of renal therapies.

Fresenius Medical Care AG is primarily present in various countries and regions across the globe. With a strong global presence, the company operates in more than 150 countries and regions, including the United States, Germany, Asia-Pacific, Latin America, and Europe. Its widespread international network enables Fresenius Medical Care AG to provide advanced renal care products, services, and solutions to patients worldwide. As the global leader in dialysis and kidney care, Fresenius Medical Care AG continues to expand its reach and impact, ensuring quality healthcare for patients globally.

Fresenius Medical Care AG represents values of quality, innovation, and patient-centered care. With a dedicated corporate philosophy, the company focuses on providing life-saving dialysis products, therapies, and services to patients worldwide. The commitment to excellence, compassion, and continuous advancement in medical technology enables Fresenius Medical Care AG to enhance patients' quality of life and deliver optimal renal care. As a global leader in the field, Fresenius Medical Care AG maintains a strong emphasis on scientific research, sustainability, and delivering efficient healthcare solutions for patients suffering from chronic kidney diseases.

Analüütikud määravad Fresenius Medical Care aktsiale keskmiseks hinnasihi 45,79 EUR (mediaan: 46,92 EUR), mis on +18,8 % viimase hinna suhtes. Konsensus põhineb 27 analüütiku hinnangul.

27 analüütikut hindavad praegu Fresenius Medical Care aktsiat: 11 soovitab osta, 9 hoida ja 7 müüa. 2026. aastaks ootavad analüütikud, et Fresenius Medical Care teenib tulu 19,49 B EUR ja kasumit aktsia kohta 4,16 EUR.

Fresenius Medical Care aktsia (FME.DE) on noteeritud 10 börsil, sh: London (0H9X.L), SIX (Zürich) (FMEEUR.SW), XETRA (FME.DE), Frankfurt (FME.F), München (FME.MU), Düsseldorf (FME.DU), Hamburg (FME.HM), Wien (FME.VI).

Fresenius Medical Care AG is a leading provider of products and services for the dialysis treatment of patients with kidney failure. The company is headquartered in Bad Homburg, Germany, and operates in over 120 countries worldwide. Fresenius Medical Care also operates its own dialysis centers and offers various other medical services. The business model of Fresenius Medical Care includes three business segments: dialysis products, services related to dialysis treatment, and the care of patients with chronic diseases. In the field of dialysis products, Fresenius Medical Care develops and produces a wide range of dialysis equipment and reagents. These products are sold to both their own dialysis centers and other medical facilities worldwide. Thanks to technological innovations in dialysis treatment, medical professionals can offer patients better outcomes and a higher quality of life. In the second business segment, Fresenius Medical Care provides services related to dialysis treatment. The company operates and manages its own dialysis centers and also provides the necessary medical professionals. Additionally, Fresenius Medical Care offers technical support and training for the use of their own dialysis products. These services are an important part of the business model as they ensure both the sales of their own products and the high-quality medical care of patients. A third business segment of Fresenius Medical Care is the care of patients with chronic diseases. Through the use of data analysis and telemedicine technologies, medical professionals from Fresenius Medical Care can actively care for patients - both online and through home visits. The goal is to improve the health of patients and avoid hospital stays. The business model of Fresenius Medical Care is based on preventive health care and support for people with chronic diseases such as kidney failure. By providing high-quality products and services and establishing a comprehensive patient care program, Fresenius Medical Care strengthens its position as a leading provider in dialysis treatment. In recent years, Fresenius Medical Care has also increased its investment in research and development of innovative treatment methods to continuously improve the quality of medical care for patients with chronic diseases. The extensive expertise in this field enables the development of new treatment modalities, including digital solutions, that benefit patients. Overall, Fresenius Medical Care is an innovative company specializing in the provision of products and services for dialysis treatment. By combining technological innovations, a comprehensive patient care program, and a constant focus on the needs of medical professionals in the global healthcare industry, the company relies on a forward-looking, promising business model in a sector of growing importance.

oodatav Fresenius Medical Care käive on 19,49 B EUR. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.

oodatav Fresenius Medical Care kasum on 1,19 B EUR. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.

Võrdlusarvud hinna ja kasumiga (P/E) Fresenius Medical Care jaoks on praegu 8,82. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Fresenius Medical Care aktsia väärtust.

Kursuse ja müügimahu suhe (P/S) Fresenius Medical Care jaoks on praegu 0,54. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Fresenius Medical Care aktsia jaoks.

Eulpooli kvaliteedinäitaja Fresenius Medical Care jaoks on 2/10.

Fresenius Medical Care ISIN on DE0005785802. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.

Fresenius Medical Care WKN on 578580. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.

Fresenius Medical Care ticker on FME.DE. Ticker-sümbol kasutatakse Fresenius Medical Care aktsiate kauplemiseks börsil.

Õiglane väärtusTerminal
33,78 EUR
Üle-/alahinnangTerminal
Õiglaselt hinnatakse
Tööstus
Tervishoiuteenijad ja teenused
Aktsiate arv
Töötajad
Tulu töötaja kohta
161 676,40 EUR
Tulukasvu keskmine 5 aastat
EBIT kasvu keskmine 5 aastat
Puhaskasumi kasvu keskmine 5 aastat
Valuuta
EUR
Börsi noteerimise algus
2. okt 1996
ISIN
DE0005785802
CUSIP
D2734Z107
SEDOL
5129074
Turukapitalisatsioon
10,77 B EURLarge Cap
52-nädala vahemik
PEG
1,26
P/E suhe
P/E e 2026
9,05
P/E e 2027
9,39
P/E e 2028
8,00
P/E e 2029
6,63
P/E e 2030
5,92
P/S
P/S e
0,54
EV/EBIT
10,93
P/B suhe
0,81
ROE (omakapitali tootlus)
ROA (varatootlus)
ROCE (kasutatud kapitali tootlus)
ROIC (investeeritud kapitali tootlus)
4,06 %
Dividend
Dividendi tootlus
3,92 %
Prognoositud dividendi tootlus
4,06 %
Väljamaksmise suhe
42,10 %
Dividendi kasv Ø5Y
1,99 %
Dividendimaksed aastas
1
Dividend makstud alates
28 aastat
Dividenti ei ole vähendatud alates
2 aastat
Dividenti on suurendatud alates
2 aastat
Dividendi mahaarvamismaks
26,38 %
Viimati värskendatud 20. nov 2026, 12:46

Fresenius Medical Care Börsiticker

DÜSSELDORF · FME.DUFRANKFURT · FME.FHAMBURG · FME.HMLONDON · 0H9X.LMILANO · FME.MIMÜNCHEN · FME.MUOTC · FMCQFSIX · FMEEUR.SWVIIN · FME.VIXETRA · FME.DE

Fresenius Medical Care FIGI

FME:GR · BBG000DHXQT2FME:GF · BBG000DHXRP4FME:GD · BBG000DHXT16FME:GY · BBG000DHXTF1FME:GS · BBG000DHXV11FME:GM · BBG000DHYWY2FME:GB · BBG000DHYXP0FME:GI · BBG000DHYYF9FME:GH · BBG000DHYYR6FMCQF:US · BBG000LYFMB4FMCQF:UV · BBG000LYHZ23FMED:IX · BBG000Q8FK57